MedPath

Daily versus alternate day oral iron supplementation for the treatment of iron deficiency anaemia in pregnancy (IronMother)

Phase 4
Completed
Conditions
Iron deficiency anaemia in pregnancy
Registration Number
2024-512064-61-00
Lead Sponsor
University College Dublin
Brief Summary

To determine whether alternate day oral iron is noninferior to daily oral iron for the treatment of iron deficiency

anaemia by comparing haemoglobin level (Hb) between the

two arms after 4 weeks of therapy

Detailed Description

Not available

Recruitment & Eligibility

Status
Ended
Sex
Female
Target Recruitment
230
Inclusion Criteria

Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol

Subjects must be aged 18 years or above at visit 1

Subjects will need to have a standard of English good enough to understand and read the information leaflet and consent form and communicate easily with the research team

A diagnosis of IDA as defined by Hb <10.5g/dL but not ≤7g/dl and a serum ferritin of <30µg/L

Singleton pregnancies

Gestational age of 14- 34 weeks’ gestation

A level of English high enough for informed consent and study participation

Exclusion Criteria

Women <18 years of age

Allergy/sensitivity to Galfer or their ingredients

Subjects unable to provide written informed consent or who require an interpreter

Known haemoglobinopathy

Severe anaemia as defined by Hb ≤7g/dl

Subjects who have any other significant disease or disorder (including inflammatory bowel disease, haemochromatosis, haemoglobinopathy, any active inflammatory diseases, malabsorptive conditions) which, in the opinion of the investigator, may either put the subject at risk by participation in the study, or may influence the result of the study.

Any underlying medical disorder or medications that the research team feel would impact iron absorption eg. Hyperemesis, Coeliac’s disease, inflammatory bowel disease, anaemia of chronic disease or anaemia related to other causes (B12/Folate), previous bariatric surgery, active PUD, haemochromatosis

Multiple pregnancy

Not taking medications in a way which could potentially hinder the absorption of iron eg. PPIs, Antacids, levothyroxine all need to be taken separately to iron

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hb levels at 4 weeks post IMP treatment

Hb levels at 4 weeks post IMP treatment

Secondary Outcome Measures
NameTimeMethod
Compliance as measured by objective pill count at 4 week assessment

Compliance as measured by objective pill count at 4 week assessment

Serum ferritin levels in both groups after 4 weeks treatment

Serum ferritin levels in both groups after 4 weeks treatment

Compliance as measured by questionnaire at 4 week assessment

Compliance as measured by questionnaire at 4 week assessment

Tolerance as measured by gastrointestinal symptom questionnaire at 4 week assessment

Tolerance as measured by gastrointestinal symptom questionnaire at 4 week assessment

Obstetric and neonatal outcomes : o Delivery outcomes (livebirth, stillbirth, NND) o Mode of delivery (OVD, SVD, LSCS) o Rates and quantitation of primary PPH o Postnatal blood transfusion in the two weeks post-delivery (Y/N, if yes for RCC no. of units) o Postnatal iron transfusion in the two weeks post-delivery o Neonatal Intensive Care Unit admission (Y/N) o Apgar scores (at 1 and 5 minutes of life as standard) o Birth weights o Most recent Hb levels at term (37-42 wks gestation)

Obstetric and neonatal outcomes : o Delivery outcomes (livebirth, stillbirth, NND) o Mode of delivery (OVD, SVD, LSCS) o Rates and quantitation of primary PPH o Postnatal blood transfusion in the two weeks post-delivery (Y/N, if yes for RCC no. of units) o Postnatal iron transfusion in the two weeks post-delivery o Neonatal Intensive Care Unit admission (Y/N) o Apgar scores (at 1 and 5 minutes of life as standard) o Birth weights o Most recent Hb levels at term (37-42 wks gestation)

Trial Locations

Locations (1)

The National Maternity Hospital

🇮🇪

Dublin 2, Ireland

The National Maternity Hospital
🇮🇪Dublin 2, Ireland
Jennifer Walsh
Site contact
0035316373216
jwalsh@nmh.ie

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.